ecrin-mdr-crcClinical2002DiarrheaColorectal NeoplasmsDiarrheaColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2007577United States2Concomitant useCPT-11Oral administrationSaltz regimenLeucovorinLVTraditional chinese medicineReduceModulate5-fluorouracilHerbal medicineIrinotecanOral doseChemotherapyAlleviateStage III and Stage IV colorectal cancerBotanical drugChinese herbal medicine5-FUCamptosarSide effectTCMECRIN MDRTerminatedfalseSafety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal CancerThe triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer. Severe diarrhea, unfortunately, is a side effect of such treatment. Preclinical studies have indicated that the botanical drug PHY906 can reduce such diarrhea without compromising the effectiveness of the chemotherapy. The primary purpose of this clinical study is to evaluate the safety, tolerability and minimum effective dose of PHY906 when administered in conjunction with the Saltz regimen.2002-02-152007577NCT00036517